Bright Minds Biosciences: Newest Psychedelics Company To Join The Nasdaq

Wall Street is welcoming yet another company working with psychedelic molecules for mental health and neurological treatments.

Bright Minds Biosciences (CSE: DRUG) received approval on Wednesday to effectively list its stock on the Nasdaq starting next Monday, November 8 under the symbol “DRUG.”

The company is developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain by using molecules derived from compounds in the psychedelic class.

“Our listing on Nasdaq marks an important corporate milestone for Bright Minds, as we continue to advance our innovative drug candidates in …

Full story available on Benzinga.com

More Bright Minds Biosciences: Newest Psychedelics Company To Join The Nasdaq